Patents by Inventor Allan L. Miller

Allan L. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for purifying granulocyte colony stimulating factor
    Patent number: 5849883
    Abstract: Processes for isolating and purifying granulocyte colony stimulating factor (G-CSF) from a G-CSF producing microorganism are disclosed. The simplified processes include steps of lysing the microorganism and separating insoluble material containing G-CSF from soluble proteinaceous material; extracting the material with deoxycholate (optionally); solubilizing and oxidizing the G-CSF in the presence of a denaturant solubilizing agent and an oxidizing agent; removing the denaturant solubilizing agent from the G-CSF; subjecting the G-CSF to ion exchange chromatography; and recovering the purified G-CSF; yet excludes other cumbersome purification steps.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: December 15, 1998
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Allan L. Miller, Jeffrey W. Andresen
  • Canine G-CSF polypeptides and pharmaceutical compositions comprising same
    Patent number: 5606024
    Abstract: Compositions and methods for treating or preventing infections in canine or feline animals which comprises administering an effective amount of granulocyte colony stimulating factor (G-CSF), are disclosed. The G-CSF may be naturally derived, or alternatively, the G-CSF and genetically engineered variants of G-CSF may be the expression products of genetically engineered prokaryotic or eukaryotic host cells.
    Type: Grant
    Filed: April 24, 1995
    Date of Patent: February 25, 1997
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Allan L. Miller
  • DNA encoding canine granulocyte colony stimulating factor (G-CSF)
    Patent number: 5472857
    Abstract: Compositions and methods for treating or preventing infections in canine or feline animals which comprises administering an effective amount of granulocyte colony stimulating factor (G-CSF), are disclosed. The G-CSF may be naturally derived, or alternatively, the G-CSF and genetically engineered variants of G-CSF may be the expression products of genetically engineered prokaryotic or eukaryotic host cells.
    Type: Grant
    Filed: July 1, 1994
    Date of Patent: December 5, 1995
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Allan L. Miller